目的 研究促肝細胞生長素對異煙肼和利福平誘導(dǎo)大鼠肝損傷的保護作用。方法 雄性SD大鼠給予異煙肼50 mg/kg+利福平100 mg/kg，建立肝損傷模型。促肝細胞生長素組在模型組的基礎(chǔ)上給予促肝細胞生長素腸溶膠囊40 mg/kg，給藥3周后，稱體質(zhì)量，計算肝系數(shù)，同時比較血清肝功能指標丙氨酸氨基轉(zhuǎn)移酶（ALT）、天冬氨酸氨基轉(zhuǎn)移酶（AST）、堿性磷酸酶（ALP）、總膽紅素（TBIL）和直接膽紅素（DBIL），肝抗氧化酶系超氧化物歧化酶（SOD）、谷胱甘肽過氧化物酶（GSH-Px）、還原型谷胱甘肽（GSH）和丙二醛（MDA）水平，切片觀察肝臟病理變化。結(jié)果 與模型組相比，促肝細胞生長素組ALT、AST顯著降低（P<0.05），ALP、TBIL和DBIL水平也表現(xiàn)出明顯的降低趨勢；肝組織SOD、GSH-Px水平顯著升高（P<0.05），MDA水平顯著降低（P<0.05），GSH水平有升高趨勢。促肝細胞生長素組肝小葉結(jié)構(gòu)清晰，炎癥細胞浸潤減少。結(jié)論 促肝細胞生長素對異煙肼和利福平誘導(dǎo)肝損傷具有保護作用，其作用機制可能與其肝再生增強因子提高肝組織抗氧化能力、抑制肝組織炎癥反應(yīng)有關(guān)。

Objective To study the protective effects of hepatocyte growth-promoting factors on liver injury induced by isoniazid and rifampicin in rats. Methods SD rats were given isoniazid 50 mg/kg + rifampicin 100 mg/kg to establish the model. The hepatocyte growth-promoting factors group was given Hepatocyte Growth-Promoting Factors Enteric-Coated Capsules 40 mg/kg on the basis of the model group. After 3 weeks' intervention, body mass was weighed and liver coefficient was calculated. And the serum liver function indexes ALT, AST, ALP, TBIL, and DBIL, and liver antioxidant enzyme system SOD, GSH-Px, GSH, and MDA were compared, the changes of hepatic pathology was observed by pathological section. Results Compared with the model group, ALT and AST in the hepatocyte growth-promoting factors group were significantly decreased (P<0.05), and ALP, TBIL, and DBIL levels also had the trend of decrease. SOD and GSH-Px levels in the hepatocyte growth-promoting factors group were significantly increased (P<0.05), but MDA level was significantly decreased (P<0.05). GSH level had the trend of increase. The structure of hepatic lobules was clear and the infiltration of inflammatory cells was reduced in the hepatocyte growth-promoting factors group. Conclusion Hepatocyte growth-promoting factors have the protective effects of liver injury induced by isoniazid and rifampicin in rats, and its mechanism may be related to the enhancement of antioxidant capacity of liver tissue and the inhibition of inflammatory response of liver tissue.

R966

浙江省2018年度重點研發(fā)計劃項目（2018C02051）